Is Baxter International (BAX) Cheap After Its Class I Recall And Segment Reshuffle?

Baxter International (BAX) is back in focus after a voluntary Class I recall of its Hillrom VOLARA System P.CIRCUIT KIT, highlighting operational and regulatory questions just as the company reshapes its financial reporting segments.

See our latest analysis for Baxter International.

The recall and segment reshuffle come after a period where Baxter International’s share price return has picked up in the short term, with a 30 day share price return of 14.13% and a 90 day share price return of 24.80%. This has occurred even as the 1 year total shareholder return declined 15.56% and the 5 year total shareholder return declined 67.91%, suggesting recent momentum contrasts with a much weaker long term experience for shareholders.

If this recall has you reassessing healthcare exposures, it may help to widen the lens and look at other opportunities in the sector using the 39 healthcare AI stocks.

Baxter International’s share price has moved sharply off its lows, yet it still trades at a discount to some fair value estimates while sitting above the average analyst target. Is the market being too cautious, or not cautious enough?

Most Popular Narrative: 8.4% Overvalued

At a last close of $23.35 versus a narrative fair value of $21.54, Baxter International is priced above that framework, which leans on detailed revenue and margin forecasts.

Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.

Read the complete narrative. Read the complete narrative.

Want to understand why an unprofitable company still carries this kind of fair value math? The core story hinges on a sharp earnings swing, firmer margins, and a richer future earnings multiple that many investors usually associate with higher growth sectors. Curious which revenue path and margin rebuild need to line up for that to make sense?

Result: Fair Value of $21.54 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on Baxter International clearing execution hurdles, with margin pressure and product quality or regulatory setbacks both capable of derailing that upbeat earnings path.

Find out about the key risks to this Baxter International narrative.

Another View on Baxter International’s Value

The narrative framework sees Baxter International as 8.4% overvalued at $23.35 versus a fair value of $21.54, while the SWS DCF model points the other way, with an estimate of $29.27, suggesting the stock trades at a 20.2% discount. Which set of assumptions do you trust more?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Mixed signals around Baxter International’s recall, valuation and earnings potential make this a good moment to review the numbers yourself, weigh both sides of the story, and see how they fit with your risk tolerance and goals using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Baxter International?

If you are reassessing Baxter International, do not stop there. Broaden your watchlist with fresh ideas that match different goals, risk levels and income needs.

• Capture potential mispricing by scanning for quality stocks trading at appealing valuations through the 49 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies that have paid-out yields of 5% or more in the 9 dividend fortresses.
• Dial down risk by focusing on resilient businesses with healthier profiles using the 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com